STVN

Stevanato Group S.p.A. (STVN) | Rumor.io

Stevanato Group

STVN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,462

Bullish sentiment (50-day avg)98%

Price to earnings ratio38.3

Market capitalization5.8B

Earnings per share0.56

Dividend yield (TTM)1.16%

Revenue (annual)1.2B

Net income (annual)139.8M

Social

What share of all stock conversation is about STVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Mar 11

Stevanato Group's revenue is growing, with GLP-1 contributing 20% and high-value syringes reaching 49% of Q4 sales with 31% growth.
The company has a strong ownership structure with 80%+ family ownership and is guiding for 9% organic growth in 2026.
Stevanato Group's stock price has fallen 48% and is considered a "best anchor stock" by some investors.

Generated by AI

Sentiment

Of the messages about STVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% 0	100% +2.86	79.19% -10.93
Bearish	0% 0	0% 0	0% -2.86	20.81% +10.93

Topics

Of the messages about STVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	88.89%	27.42%
Earnings	—	0%	0%	12.12%
Technical Analysis	—	0%	11.11%	1.84%
Macro	—	0%	0%	55.57%
Analysts	—	0%	0%	3.06%
Controversies	—	0%	0%	0%

Analysts· Mar 9

Morgan Stanley cut Stevanato Group's price target to $22.00, maintaining an overweight rating.
Bank of America and Wells Fargo also lowered Stevanato Group's price targets to $24.00 and $21.00, respectively, while maintaining buy and overweight ratings.
Citigroup, B of A Securities, and Wells Fargo analysts lowered Stevanato Group's price targets to $23.00, $24.00, and $21.00, respectively, while maintaining buy ratings.

Announcements· Mar 2

Stevanato Group S.p.A. reported FY22 financial results, with a 9% increase in backlog, revenue of $983.7M, and an operating profit margin of 19.6%.
The company's shares traded 6.18% higher, with the stock rising 8.6% after the report, driven by a year-over-year increase in Q4 revenue and guidance for growth in FY23 revenue.
Stevanato Group established FY 2023 guidance, with revenue expected to be in the range of EUR 1.085 bln to EUR 1.115 bln, and adjusted diluted EPS between EUR 0.58 and EUR 0.62.

Generated by AI

Community

Of the messages about STVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	3.03%	6.58%	56.53%
Newcomers	100%	96.97%	93.42%	43.47%

Regulars· Mar 2

Stevanato Group S.p.A. reported Q4 and FY 2022 financial results, with revenue of €292.1M and non-GAAP EPS of €0.19.
The company's shares climbed 6.2% past the previous 52-week high, with trading volume 43% above average.
Stevanato Group's Q4 earnings and revenue estimates were surpassed, according to the company's latest 6-K filing.

Newcomers· Aug 20

The Stevanato Group S.p.A. has announced its second quarter 2021 financial results, with expected annual growth of 33-35%.
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on Stevanato Group with a raised price target of $28.
The stock has reacted well to its pre-market earnings report, spiking 13.5% and making it one of the trending stocks.

Generated by AI

News

UBS Adjusts Price Target on Stevanato Group to $23 From $28, Keeps Neutral Rating

Stevanato Group SpA (STVN) has an average rating of overweight and mean price target of $25.16, acco

21d agoYahoo Finance

Stevanato Group to Participate in Two Upcoming Investor Conferences

PIOMBINO DESE, Italy, September 08, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences:

21d agoYahoo Finance

Stevanato Group (STVN) Trades A Subsidiary For Margin Gains And Growth

On August 4, Stevanato Group (NYSE:STVN) reported second-quarter revenue of €302.0 million, up 8% year over year, while also closing the sale of its California-based subsidiary, Balda C. Brewer Inc. The results paired steady growth in the company’s core drug containment and delivery business with a portfolio move that reshaped its bottom line for the […]

25d agofinance.yahoo.com

Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches

Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]

28d agoYahoo! Finance Canada

Stevanato Group: Alina Validates The Container-To-Device Flywheel (NYSE:STVN)

Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform. Learn why STVN stock is a buy.

1mo agoSeeking Alpha

Morgan Stanley Releases a Hold Rating on Stevanato Group (STVN)

Detailed price information for Stevanato Group S.P.A. (STVN-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about STVN also mention

#	Name	Attention
1	ASGN Inc.ASGN	0%0
2	West Pharmaceutical Services Inc.WST	0%0
3	Medpace Holdings, Inc.MEDP	0%+0
4	PennyMac Financial Services, Inc. Common StockPFSI	0.01%new
5	ICON plcICLR	0%0
6	Lyell Immunopharma, Inc.LYEL	0.01%new
7	PWSC - PowerSchool Holdings, Inc.	——
8	RPM International Inc.RPM	0%0
9	Installed Building Products, Inc.IBP	0%0
10	Repligen CorporationRGEN	0%new

Stevanato Group S.p.A.

Healthcare
Medical Instruments & Supplies

Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle. Its portfolio includes containment systems such as vials, cartridges, syringes, and ampoules, alongside drug delivery devices, diagnostic consumables, analytical services, and medical devices. Stevanato Group also offers engineering capabilities through visual inspection, assembling, packaging, and glass-forming machinery, supporting manufacturing and packaging operations for biopharma customers. Headquartered in Piombino Dese, Italy, the company serves a global customer base across multiple healthcare and diagnostic markets.

Website

Location

Via Molinella 17

Piombino Dese, PD, 35017

Italy

Social

What share of all stock conversation is about STVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Mar 11

Stevanato Group's revenue is growing, with GLP-1 contributing 20% and high-value syringes reaching 49% of Q4 sales with 31% growth.
The company has a strong ownership structure with 80%+ family ownership and is guiding for 9% organic growth in 2026.
Stevanato Group's stock price has fallen 48% and is considered a "best anchor stock" by some investors.

Generated by AI

Sentiment

Of the messages about STVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% 0	100% +2.86	79.19% -10.93
Bearish	0% 0	0% 0	0% -2.86	20.81% +10.93

Topics

Of the messages about STVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	88.89%	27.42%
Earnings	—	0%	0%	12.12%
Technical Analysis	—	0%	11.11%	1.84%
Macro	—	0%	0%	55.57%
Analysts	—	0%	0%	3.06%
Controversies	—	0%	0%	0%

Analysts· Mar 9

Morgan Stanley cut Stevanato Group's price target to $22.00, maintaining an overweight rating.
Bank of America and Wells Fargo also lowered Stevanato Group's price targets to $24.00 and $21.00, respectively, while maintaining buy and overweight ratings.
Citigroup, B of A Securities, and Wells Fargo analysts lowered Stevanato Group's price targets to $23.00, $24.00, and $21.00, respectively, while maintaining buy ratings.

Announcements· Mar 2

Stevanato Group S.p.A. reported FY22 financial results, with a 9% increase in backlog, revenue of $983.7M, and an operating profit margin of 19.6%.
The company's shares traded 6.18% higher, with the stock rising 8.6% after the report, driven by a year-over-year increase in Q4 revenue and guidance for growth in FY23 revenue.
Stevanato Group established FY 2023 guidance, with revenue expected to be in the range of EUR 1.085 bln to EUR 1.115 bln, and adjusted diluted EPS between EUR 0.58 and EUR 0.62.

Generated by AI

Community

Of the messages about STVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	3.03%	6.58%	56.53%
Newcomers	100%	96.97%	93.42%	43.47%

Regulars· Mar 2

Stevanato Group S.p.A. reported Q4 and FY 2022 financial results, with revenue of €292.1M and non-GAAP EPS of €0.19.
The company's shares climbed 6.2% past the previous 52-week high, with trading volume 43% above average.
Stevanato Group's Q4 earnings and revenue estimates were surpassed, according to the company's latest 6-K filing.

Newcomers· Aug 20

The Stevanato Group S.p.A. has announced its second quarter 2021 financial results, with expected annual growth of 33-35%.
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on Stevanato Group with a raised price target of $28.
The stock has reacted well to its pre-market earnings report, spiking 13.5% and making it one of the trending stocks.

Generated by AI

Stevanato Group

Social

Mar 11

Analysts· Mar 9

Announcements· Mar 2

Regulars· Mar 2

Newcomers· Aug 20

UBS Adjusts Price Target on Stevanato Group to $23 From $28, Keeps Neutral Rating

Stevanato Group to Participate in Two Upcoming Investor Conferences

Stevanato Group (STVN) Trades A Subsidiary For Margin Gains And Growth

Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches

Stevanato Group: Alina Validates The Container-To-Device Flywheel (NYSE:STVN)

Morgan Stanley Releases a Hold Rating on Stevanato Group (STVN)

Also Discussed

Stevanato Group S.p.A.

Company Information

Location

UBS Adjusts Price Target on Stevanato Group to $23 From $28, Keeps Neutral Rating

Stevanato Group to Participate in Two Upcoming Investor Conferences

Stevanato Group (STVN) Trades A Subsidiary For Margin Gains And Growth

Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches

Stevanato Group: Alina Validates The Container-To-Device Flywheel (NYSE:STVN)

Morgan Stanley Releases a Hold Rating on Stevanato Group (STVN)

Also Discussed

Social

Mar 11

Analysts· Mar 9

Announcements· Mar 2

Regulars· Mar 2

Newcomers· Aug 20